These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 15637527)
1. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Yasui-Furukori N; Uno T; Sugawara K; Tateishi T Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527 [TBL] [Abstract][Full Text] [Related]
2. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315 [TBL] [Abstract][Full Text] [Related]
3. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446 [TBL] [Abstract][Full Text] [Related]
4. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801 [TBL] [Abstract][Full Text] [Related]
5. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Dresser GK; Kim RB; Bailey DG Clin Pharmacol Ther; 2005 Mar; 77(3):170-7. PubMed ID: 15735611 [TBL] [Abstract][Full Text] [Related]
6. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. Olsén L; Ingvast-Larsson C; Larsson P; Broström H; Bondesson U; Sundqvist M; Tjälve H J Vet Pharmacol Ther; 2006 Apr; 29(2):129-35. PubMed ID: 16515667 [TBL] [Abstract][Full Text] [Related]
7. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651 [TBL] [Abstract][Full Text] [Related]
8. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853 [TBL] [Abstract][Full Text] [Related]
9. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Uno T; Shimizu M; Sugawara K; Tateishi T Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786 [TBL] [Abstract][Full Text] [Related]
10. The effect of rifampin administration on the disposition of fexofenadine. Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975 [TBL] [Abstract][Full Text] [Related]
11. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383 [TBL] [Abstract][Full Text] [Related]
12. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of fexofenadine enantiomers. Miura M; Uno T Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats. Qiang F; Lee BJ; Lee W; Han HK Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223 [TBL] [Abstract][Full Text] [Related]
15. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Petri N; Bergman E; Forsell P; Hedeland M; Bondesson U; Knutson L; Lennernäs H Drug Metab Dispos; 2006 Jul; 34(7):1182-9. PubMed ID: 16621934 [TBL] [Abstract][Full Text] [Related]
16. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Shimizu M; Uno T; Sugawara K; Tateishi T Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847 [TBL] [Abstract][Full Text] [Related]
17. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Bailey DG; Dresser GK; Leake BF; Kim RB Clin Pharmacol Ther; 2007 Apr; 81(4):495-502. PubMed ID: 17301733 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Miura M; Uno T; Tateishi T; Suzuki T Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Tahara H; Kusuhara H; Maeda K; Koepsell H; Fuse E; Sugiyama Y Drug Metab Dispos; 2006 May; 34(5):743-7. PubMed ID: 16455804 [TBL] [Abstract][Full Text] [Related]
20. Effect of St John's wort on the pharmacokinetics of fexofenadine. Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]